eduKateSG · Why Science?
Study airways, pathogens, hosts and populations together—connecting mechanism, surveillance, antimicrobial resistance, trials and public-health action
A fact-checked guide to LKCMedicine’s Respiratory & Infectious Diseases programme and its multidisciplinary research on major and emerging health threats.
LKCMedicine says its Respiratory & Infectious Diseases programme addresses major threats and emerging infections, including antimicrobial resistance, asthma and vector-borne disease.
Its official page highlights microbiology, virology, systems biology and genomics alongside partnerships and facilities including TARIPH, a Biosafety Level 3 laboratory and TRIDENT.
Did you know? The same pathogen can produce different outcomes because transmission, dose, host immunity, airway condition and access to care all interact.
This guide provides no diagnosis, testing or treatment advice. Sources were checked 11 November 2026.
Chapter index
Chapters 1–9: respiratory science, infectious disease, airway systems, pathogen biology, host response, microbiology, virology, antimicrobial resistance, genomics
Chapters 10–17: systems biology, asthma, tuberculosis, vector-borne disease, emerging infections, human challenge models, trials, climate and evidence receipts
CHAPTER 1 OF 17 · Map interacting systems
1. Connect respiratory and infectious science
Airway health and infection interact through anatomy, physiology, microbes, immunity and environment. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 1 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Frame questions across biological and population scales. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
Not every respiratory disease is infectious, and not every infection begins in the lungs. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Connect respiratory and infectious science” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Draw a systems map. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 1 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Airways exchange gases while filtering particles and coordinating mechanical and immune defences. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 2 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Measure structure, airflow, gas exchange and symptoms separately. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
One lung-function value cannot explain every breathing problem. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Understand respiratory systems” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Build a respiratory model. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 2 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Pathogens vary in genomes, structures, life cycles and dependencies. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 3 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Match the organism and life stage to suitable assays. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
Detection of genetic material may not show viable transmission. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Study pathogen biology” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Create a pathogen profile. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 3 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Innate and adaptive responses can control infection, cause pathology or shape recovery. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 4 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Measure cells, signals, timing, site and function. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
A raised immune marker does not identify one cause. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Map host responses” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Draw a host-response timeline. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 4 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
| Evidence move | What to record | What it cannot prove alone |
|---|---|---|
| Respiratory system question | Population, variable, unit and time window | A definition does not establish a result |
| Comparison | Baseline, comparator and uncertainty | Association alone does not establish cause |
| Decision boundary | Owner, trigger, review and escalation | A model does not replace accountable judgement |
Microbiology grows, detects or characterises microbes under controlled conditions. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 5 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Use reference controls, contamination checks and authorised containment. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
Culture conditions may select only part of a community. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Use microbiology” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Audit a fictional assay. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 5 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Virology studies viral entry, replication, evolution and host interaction. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 6 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Choose safe models and validated molecular or immunological readouts. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
A cell-culture effect may not predict human disease. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Use virology” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Build a viral life-cycle map. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 6 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Resistance emerges and spreads through mutation, gene transfer, selection and connected ecosystems. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 7 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Combine susceptibility testing, genomics and exposure data. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
A resistance gene does not always predict expressed clinical resistance. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Investigate antimicrobial resistance” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Create an AMR evidence table. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 7 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Sequencing can compare variants, infer relatedness and support surveillance. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 8 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Record sampling, coverage, quality, reference and uncertainty. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
Genetic similarity alone cannot prove direct transmission. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Apply pathogen genomics” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Audit a genomic claim. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 8 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
| Evidence move | What to record | What it cannot prove alone |
|---|---|---|
| Microbe question | Population, variable, unit and time window | A definition does not establish a result |
| Comparison | Baseline, comparator and uncertainty | Association alone does not establish cause |
| Decision boundary | Owner, trigger, review and escalation | A model does not replace accountable judgement |
Systems biology integrates molecular, cellular and clinical measurements into testable networks. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 9 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Use explicit assumptions and independent validation. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
A fitted network is not automatically a causal mechanism. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Build systems-biology models” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Create a systems model card. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 9 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
CHAPTER 10 OF 17 · Follow disease patterns
10. Study asthma and chronic airway disease
Asthma and other chronic airway conditions involve heterogeneous inflammation, physiology and exposures. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 10 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Use phenotypes, longitudinal measures and meaningful outcomes. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
One inflammatory marker does not define every patient pathway. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Study asthma and chronic airway disease” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Build a heterogeneity map. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 10 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
CHAPTER 11 OF 17 · Follow disease patterns
11. Research tuberculosis and mycobacteria
Mycobacteria pose distinctive biological, treatment and resistance challenges. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 11 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Connect models, drug susceptibility, host response and clinical evidence. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
Laboratory killing does not guarantee a safe effective regimen. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Research tuberculosis and mycobacteria” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Draw a drug-development ladder. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 11 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Vectors connect pathogen biology with climate, ecology, behaviour and human exposure. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 12 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Measure vector abundance, infection, contact and cases across time. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
More vectors do not directly equal more clinical disease. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Study vector-borne disease” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Build a vector pathway. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 12 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
| Evidence move | What to record | What it cannot prove alone |
|---|---|---|
| Surveillance question | Population, variable, unit and time window | A definition does not establish a result |
| Comparison | Baseline, comparator and uncertainty | Association alone does not establish cause |
| Decision boundary | Owner, trigger, review and escalation | A model does not replace accountable judgement |
Preparedness combines surveillance, diagnostics, biosafety, clinical research and coordinated response. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 13 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Predefine triggers, roles, data flows and review points. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
Prediction cannot specify every future pathogen or outbreak. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Prepare for emerging infections” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Draft a preparedness map. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 13 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Controlled challenge studies can examine infection and immunity under strict ethical and clinical safeguards. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 14 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Define consent, eligibility, rescue treatment and stopping rules. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
A selected volunteer model cannot represent all populations. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Understand human challenge models” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Build an ethics boundary. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 14 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Translational studies move from mechanism and preclinical evidence to phased clinical evaluation. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 15 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Use safety, immunogenicity or efficacy endpoints appropriate to the stage. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
Early biological response does not establish population benefit. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Test drugs and vaccines” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Create a trial ladder. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 15 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
Climate and environmental change can alter vectors, exposures, air quality and health-system risks. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 16 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Combine environmental, biological and social data over suitable timescales. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
A seasonal correlation cannot establish a climate mechanism. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Connect climate and health” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Draw a climate-health pathway. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 16 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
The receipt links pathogen or process, host, sample, method, time, outcome and action boundary. Respiratory and infectious-disease science studies lungs, microbes, hosts, transmission, immunity and environments as interacting systems. LKCMedicine says its programme addresses antimicrobial resistance, asthma, vector-borne disease and emerging infections through microbiology, virology, systems biology, genomics and translational partnerships. Chapter 17 connects mechanism with surveillance, prevention and carefully evaluated intervention.
Archive protocols, controls, sequence versions, exclusions and uncertainty. Strong studies specify the pathogen or respiratory process, host population, exposure, specimen, timing, assay, comparator and outcome. Culture, sequencing, imaging, physiology, immune profiling, epidemiology and trials provide different evidence. Controls, biosafety, calibration, longitudinal sampling and independent replication help separate a causal mechanism from contamination, selection bias or a changing epidemic context.
Documentation cannot authorise clinical or outbreak action. Infection and breathing symptoms require caution. A laboratory result, sequence, environmental exposure or model cannot diagnose or guide treatment for a person by itself; resistance patterns vary; and an animal or challenge model cannot reproduce every community condition. Qualified clinicians, public-health authorities, ethics boards, biosafety systems and current guidance govern real testing, treatment and outbreak response.
Investigate “Keep a respiratory-infectious receipt” with a fictional transmission or airway dataset. Define the population, biological sample, exposure window, measurement, confounders, control group and safety boundary, then choose the next evidence step. Assemble a one-page receipt. Do not culture unknown microbes, collect clinical samples, change medicines or expose anyone. Use safe paper models and public, de-identified data only.
Did you know? A respiratory pathogen can be shaped simultaneously by microbial genetics, immune history, airways, behaviour, climate, travel and healthcare systems. Chapter 17 shows why researchers combine laboratory mechanisms with genomic surveillance, clinical cohorts and population data instead of expecting one test or one discipline to explain an outbreak or chronic disease.
Capabilities include microbiology, virology, immunology, respiratory physiology, genomics, bioinformatics, pharmacology, epidemiology, entomology, climate science, clinical trials and public health. Current laboratories and professions set qualifications and biosafety rules. Students can begin with safe models, growth curves, probability, sequence comparisons, causal diagrams and clear communication about uncertainty and collective protection.
| Evidence move | What to record | What it cannot prove alone |
|---|---|---|
| Respiratory and infectious disease question | Population, variable, unit and time window | A definition does not establish a result |
| Comparison | Baseline, comparator and uncertainty | Association alone does not establish cause |
| Decision boundary | Owner, trigger, review and escalation | A model does not replace accountable judgement |
Contents · Previous chapter · Continue in the Science Learning Hub
Primary sources and verification date
Source status for Why Science? | Respiratory & Infectious Diseases was checked 11 November 2026. Research priorities, programmes, recruitment, facilities and participation routes can change; use the linked official owner for the current edition.
- Respiratory & Infectious Diseases — Official current programme focus, platforms, partnerships and impact.
- LKCMedicine research programmes — Official current research-programme map.
- TARIPH — Official linked respiratory and infectious-disease research platform.
- LKCMedicine research overview — Official institutional research and translation context.
Continue the evidence journey
Respiratory and infectious-disease science protects health when mechanisms, surveillance, clinical evidence and public action remain connected without turning uncertain signals into personal or population conclusions. Families considering science tuition or a science tutor can use the same evidence questions: what will the learner practise, what feedback will they receive, and how will progress be shown?